NIH grants over $500 million to develop antiviral drugs for potential future pandemics
- Smoking seriously hurts human brains
- Why are vegetarians more likely to suffer from depression than meat eaters?
- Small wireless device implanted between skin and skull helps kill cancer cells
- Will the mRNA vaccine that can cure cancer come out near soon?
- Allogeneic T-cell therapy set for landmark first approval
- Boston University denies that the new COVID strain they made has 80% fatality rate
NIH grants over $500 million to develop antiviral drugs for potential future pandemics
- First human trial of HIV gene therapy: A one-time cure will be achieved if successful!
- New breakthrough in CAR-T cell therapy: Lupus erythematosus patients achieved treatment-free remission for up to 17 months
- How long can the patient live after heart stent surgery?
- First time: Systemic multi-organ recovery after death
- Where do the bacteria in the human gut come from?
NIH grants over $500 million to develop antiviral drugs for potential future pandemics
The National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health (NIH), has awarded approximately $577 million to establish nine Pandemic Pathogen Antiviral Drug Discovery (AViDD) centers.
The AViDD Center will conduct innovative multidisciplinary research to develop candidate COVID-19 antivirals, as well as antivirals targeting specific virus families that may cause future pandemics, including paramyxoviruses, bunyaviruses, togaviruses , filoviruses (including Ebola virus and Marburg virus), picornaviruses (including enteroviruses and other viruses that cause colds), flaviviruses (including those that cause yellow fever, dengue fever, and Zika), etc. .
The grant is part of the Pandemic Antiviral Initiative, an intensive research program aimed at accelerating the development of treatments for COVID-19.
The AViDD Center will conduct early identification and validation studies of novel viral targets, with a focus on identifying small molecules and biotherapeutics that directly block viral targets.
After drug candidates are identified and properties such as potency and breadth are evaluated, the most promising drugs move into late-stage preclinical development.
“Our hope is that research on antiviral drugs will better prepare us for the next pandemic,” said NIAID Director Dr. Anthony S. Fauci.
References:
[1] NIH announces antiviral drug development awards. Retrieved May 18, 2022, from https://www.nih.gov/news-events/news-releases/nih-announces-antiviral-drug-development-awards
(source:internet, reference only)
Disclaimer of medicaltrend.org
